A Phase 2 Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Andrew B LassmanPatrick Y WenMartin J Van Den BentScott R PlotkinAnnemiek M E WalenkampAdam L GreenKai LiChristopher J WalkerHua ChangSharon TamirLeah HenegarYao ShenMariano J AlvarezAndrea CalifanoYosef LandesmanMichael G KauffmanSharon SachamMorten Mau SorensenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
At 80mg weekly, single-agent selinexor induced responses and clinically relevant PFS6 with manageable side effects requiring dose reductions. Ongoing trials are evaluating safety and efficacy of selinexor in combination with other therapies for newly diagnosed or recurrent glioblastoma.